Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension (PAH) Subjects
Completed
Conditions studied: Hypertension, Pulmonary
In brief
GlaxoSmithKline (GSK) is embarking on a clinical program to assess the treatment of PAH with an Angiotensin converting enzyme 2 (ACE2). This new treatment may require subcutaneous administration, in comparison to current treatments which are taken orally. Hence, GSK would like to conduct this qualitative interview study with PAH subjects to explore subject's perspective and preferences for various modes of treatment administration (daily or weekly subcutaneous injection versus current treatment options). This will be a qualitative study comprising the conduct of semi-structured telephone concept elicitation interviews with 8 to 10 PAH subjects (each approximately 30 minutes in duration) in the United States (US).
Key facts
- Study ID
- NCT03304548
- Run by
- GlaxoSmithKline
- People needed
- 10
- Starts
- 2017-11-22
- Expected to finish
- 2018-04-10
- Last updated by the study team
- 2019-04-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male or female, at least 18 years of age.
- Subject is willing and able to provide written informed consent.
- Subject must have a diagnosis of symptomatic Pulmonary Arterial Hypertension Type I as per the World Health Organization (WHO) clinical classification system.
- Subject must have the cognitive and linguistic capabilities sufficient to allow them to actively participate in an interview lasting 30 minutes.
You may not qualify if…
- Subject has a diagnosis of other cardiac or pulmonary disease.
- Subject has a Type II-V diagnosis of PAH, as per the WHO clinical classification system.
- Subject is currently receiving treatment for PAH via modes of administration other than intravenously or orally.
Where it is running
- GSK Investigational Site — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.